Effect of Roscovitine and mifepristone in luminal breast cancer cells

Abstract

The cyclin dependent kinase (CDK)4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) have been recently approved in combination with endocrine therapy for luminal breast cancer treatment. On the other hand, the use of CDK2 inhibitors, such as Roscovitine, appears as a therapeutic alternative to overcome the acquisition of resistance to Palbociclib. However, there are few clinical trials using CDK2 inhibitors for breast cancer treatment. Most of the reports on the effects of Roscovitine were performed in MCF-7 or MDA-MB-231 cells.